Otsuka Pharmaceutical Co., Ltd.
2-9 Kanda Tsukasa-cho
Chiyoda-ku
Tokyo
101-8535
Tel: 03-3292-0021
Website: http://www.otsuka.co.jp/
Email: wwwadmin@tky.otsuka.co.jp
219 articles about Otsuka Pharmaceutical Co., Ltd.
-
Otsuka Pharmaceutical and Lundbeck Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer’s Dementia Treated with Brexpiprazole
6/27/2022
Results from a Phase 3 clinical study for treatment of agitation in patients with Alzheimer’s dementia showed that patients treated with brexpiprazole had a statistically significantly greater reduction in agitation compared to placebo.
-
Akebia Therapeutics’s partner Otsuka Pharmaceutical Co. announced plans to terminate its global license agreements with Akebia for vadadustat.
-
Bristol Myers Squibb’s Phase III CheckMate -816 trial hit the primary endpoint in an interim analysis.
-
Akebia Announces Otsuka's Submission of Initial Marketing Authorization Application to the European Medicines Agency for Vadadustat for the Treatment of Patients with Anemia due to Chronic Kidney Disease
10/29/2021
Akebia Therapeutics, Inc and its collaborator, Otsuka Pharmaceutical Co., Ltd. (Otsuka), today announced that Otsuka Pharmaceutical Netherlands B.V. has submitted an initial marketing authorization application (MAA) to the European Medicines Agency for vadadustat,
-
Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka
10/27/2021
Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced the signing of a master supply and services agreement with Otsuka Pharmaceutical Co., Ltd.
-
Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration
9/30/2021
Sunovion Pharmaceuticals Inc.,its parent company Sumitomo Dainippon Pharma Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced that the companies have entered into a worldwide license agreement for the joint development and commercialization of four compounds: ulotaront, non-racemic ratio of amisulpride enantiomers, SEP-378614 and SEP-380135.
-
The companies said the collaboration recognizes a “great need for novel treatments in the area of neuropsychiatric medicine development.”
-
The Canadian biotech announced the acquisition of two new pipeline assets that align with its focus on autoimmune and kidney-related disease.
-
Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA)
6/25/2021
Aurinia Pharmaceuticals Inc. announced that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd., filed an initial Marketing Authorization Application for voclosporin for the treatment of lupus nephritis to the European Medicines Agency. LN is a complication of the autoimmune disease systemic lupus erythematosus that seriously impacts the kidneys.
-
Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis
6/1/2021
Akebia Therapeutics, Inc. and its collaborator, Otsuka Pharmaceutical Co., Ltd., announced that the U.S. Food and Drug Administration accepted for filing the New Drug Application for vadadustat for the treatment of anemia due to chronic kidney disease in both adult patients on dialysis and adult patients not on dialysis.
-
Otsuka and Lundbeck Announce Decision to Continue Phase III Clinical Trial Evaluating Brexpiprazole for Treatment of Agitation in Patients With Alzheimer's-type Dementia
4/13/2021
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announce the decision to continue the recruitment of patients in the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type.
-
Otsuka and Akebia Announce Submission of New Drug Application to the FDA for Approval of Akebia’s Vadadustat
3/30/2021
Indications for renal anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis-dependent adult patients
-
Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders
3/16/2021
Perception Neuroscience, an atai Life Sciences company focused on developing innovative therapies in neuropsychiatric disorders, and Otsuka Pharmaceutical Co., Ltd., announce a collaboration and licensing agreement for the development and commercialization of Perception's lead molecule, PCN-101 in Japan as a potential treatment for mood disorders such as major depressive disorder and treatment-resistant depression.
-
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
12/17/2020
Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments
-
Immuneering Enters Collaboration with Astex Pharmaceuticals to Identify Novel Therapeutic Targets in Central Nervous System Disorder Using Disease Cancelling Technology
6/25/2020
Immuneering Corporation announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals, a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., to identify novel therapeutic targets for an undisclosed neurodegenerative disease.
-
Otsuka Announces Positive Top-line Results from Two Phase 3 Studies of Centanafadine for the Treatment of Attention-deficit Hyperactivity Disorder (ADHD) in Adult Patients
6/11/2020
Centanafadine, an investigational compound for the treatment of ADHD, demonstrated statistically significant improvements vs. placebo for primary and key secondary efficacy endpoints in both studies In the combined analysis of tolerability across the two studies, no adverse event was reported by more than 7 percent of patients An estimated 5 percent (11 million) adults in the U.S. are diagnosed with ADHD 1 TOKYO &
-
CORRECTING and REPLACING Sozosei Foundation Donates $439,000 to Support Those With Mental Health and Kidney Diseases
4/24/2020
Grants Distributed to Four Non-Profit Organizations Serving Patients, Healthcare Workers and Their Families Dealing with the Impact of COVID-19
-
Sozosei Foundation Donates $439,000 to Support Those With Mental Health and Kidney Diseases
4/23/2020
Grants Distributed to Four Non-Profit Organizations Serving Patients, Healthcare Workers and Their Families Dealing with the Impact of COVID-19
-
BioSpace Global Roundup, April 23
4/23/2020
Biopharma and life sciences groups from across the globe provide updates on their business and pipelines. -
Esperion and Otsuka Team Up for Cardiovascular Drug Development and Commercialization in Japan
4/21/2020
The collaboration for development and commercialization combines Esperion's knowledge in lipid management and Otsuka's extensive cardiovascular drug advancement and marketing in Japan.